Radiation Center of Greater Nashua now offering PLUVICTO® for advanced prostate cancer
Community-based radioligand therapy brings an important targeted treatment closer to eligible patients and families NASHUA, N.H. – The Radiation Center of Greater Nashua (RCGN) is now offering PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), an FDA-approved targeted radioligand therapy for certain adults with advanced prostate cancer. The community-based program gives eligible patients access to this specialized…
